Clinical Trial

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-30
Trial Details
NCT Number NCT06952530
Lead Sponsor Eli Lilly and Company
Conditions Hypertension
Enrollment 487 participants
Start Date 2025-04-30
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-29